Procore stock price target raised to $90 from Goldman Sachs on stabilizing growth
Investing.com - Stephens initiated coverage on Twist Bioscience (NASDAQ:TWST) with an Overweight rating and a $41.00 price target on Tuesday. This target represents a 30% upside from the current price of $31.57, which InvestingPro data shows is closely aligned with its Fair Value estimate.
The research firm highlighted Twist’s differentiated, technology-driven DNA synthesis platform that serves synthetic biology, next-generation sequencing (NGS), and drug discovery markets. Stephens noted that the company’s proprietary silicon chip technology, inspired by semiconductor manufacturing, provides advantages in cost, speed, and scale. This innovation has helped drive Twist’s impressive 22.7% revenue growth over the last twelve months and a robust five-year revenue CAGR of 42%.
Despite intense competition, Stephens believes Twist’s cost leadership and previous investments are driving market share gains and positioning the company to reach adjusted EBITDA break-even by the end of fiscal year 2026. InvestingPro data confirms the company is not currently profitable, with an EBITDA of -$119.46 million, though its financial health score is rated as GOOD with liquid assets exceeding short-term obligations.
The firm identified NGS as offering meaningful growth potential, particularly from liquid biopsy and minimal residual disease (MRD) adoption, while platform expansion into adjacent markets continues to strengthen customer relationships.
Stephens assigned the $41 price target based on 5.1x calendar year 2026 revenue, noting that while the path to profitability is not fully de-risked, the firm sees "a growing line of sight driven by strategic execution and commercial momentum" that creates an attractive risk/reward profile. Investors should note that InvestingPro identifies TWST as having volatile price movements with a high beta of 2.39 and a recent one-week decline of nearly 6%. Discover more insights and 7 additional ProTips in the comprehensive Pro Research Report available for Twist Bioscience.
In other recent news, Twist Bioscience Corporation has introduced a new sequencing solution in collaboration with Element Biosciences. This solution, named the Trinity Freestyle Fast Hybridization workflow, allows researchers to process samples in as little as five hours. Additionally, Twist Bioscience was involved in a study led by Microsoft, which highlighted potential biosecurity gaps in genetic screening due to AI-designed protein variants. The study emphasized the need for updated biosecurity measures as AI technology advances in biological applications.
In corporate governance updates, Twist Bioscience appointed Trynka Shineman Blake to its board of directors. She will also serve on the audit committee, bringing her extensive experience from her previous role as CEO of Vistaprint. On the financial front, JPMorgan has lowered its price target for Twist Bioscience to $25, maintaining an Underweight rating. Meanwhile, TD Cowen adjusted its price target to $36, keeping a Buy rating, citing changes in the company’s fiscal year 2025 guidance related to Next-Generation Sequencing revenue.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.